[Recent developments of pharmacogenomics in the treatment of colorectal cancers].

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Annales Pharmaceutiques Françaises

• Publication date

  2010-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.pharma.2010.04.001PMID 20637356
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Monoclonal Antibodies Targeting Vascular Endothelial Growth Factor

  2012cited by this paper
• The predictive value of genetic variations in the vascular endothelial growth factor A gene in metastatic colorectal cancer

  2011cited by this paper
• Methylene tetrahydrofolate reductase gene polymorphism in Egyptian children with acute lymphoblastic leukemia

  2010cited by this paper
• Genotype-driven phase I study of irinotecan administered in combination with fluorouracil/leucovorin in patients with metastatic colorectal cancer.

  2010influential reference
• The long road to colorectal cancer therapy: searching for the right signals.

  2010influential reference
• The Pharmacogenomics of Membrane Transporters Project: Research at the Interface of Genomics and Transporter Pharmacology

  2010cited by this paper
• Methylenetetrahydrofolate reductase gene polymorphisms and risk of acute lymphoblastic leukemia in children.

  2010cited by this paper
• MTHFR C677T polymorphism associated with breast cancer susceptibility: a meta-analysis involving 15,260 cases and 20,411 controls

  2010cited by this paper
• Acquired hemophilia A: three different presentations of the same disease.

  2010cited by this paper
• The Role of Vascular Endothelial Growth Factor Genetic Variability in Cancer

  2009cited by this paper
• Single nucleotide polymorphism in ABCG2 is associated with irinotecan-induced severe myelosuppression

  2009cited by this paper
• PTEN status in advanced colorectal cancer treated with cetuximab

  2009cited by this paper
• Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3.

  2009cited by this paper
• Biomarkers of response and resistance to antiangiogenic therapy

  2009influential reference
• Pharmacogenomics and -genetics in colorectal cancer.

  2009cited by this paper
• KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: practical application of patient selection.

  2009cited by this paper
• Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics.

  2009cited by this paper
• Does microsatellite instability predict the efficacy of adjuvant chemotherapy in colorectal cancer? A systematic review with meta-analysis.

  2009cited by this paper
• Oxaliplatin or irinotecan as adjuvant therapy for colon cancer: the results are in.

  2009cited by this paper
• Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial.

  2009cited by this paper
• Targeting metastatic colorectal cancer in 2008: a long way from 5-FU.

  2008cited by this paper
• Cancer Statistics, 2008

  2008cited by this paper
• Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.

  2008cited by this paper
• Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.

  2008cited by this paper
• Cancers digestifs

  2008cited by this paper
• Prognostic significance of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase protein expression in colorectal cancer patients treated with or without 5-fluorouracil-based chemotherapy.

  2008cited by this paper
• HPLC with UV or mass spectrometric detection for quantifying endogenous uracil and dihydrouracil in human plasma.

  2008cited by this paper
• Gefitinib in Combination with Oxaliplatin and 5-Fluorouracil in Irinotecan-Refractory Patients with Colorectal Cancer: A Phase I Study of the Arbeits gemeinschaft Internistische Onkologie (AIO)

  2008cited by this paper
• KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience

  2008cited by this paper
• Confirmation of deficient mismatch repair (dMMR) as a predictive marker for lack of benefit from 5-FU based chemotherapy in stage II and III colon cancer (CC): A pooled molecular reanalysis of randomized chemotherapy trials

  2008cited by this paper
• EGFR antagonists in cancer treatment.

  2008cited by this paper
• Individualization of therapy based on clinical and molecular parameters

  2008cited by this paper
• Irinotecan‐induced Diarrhea: Functional Significance of the Polymorphic ABCC2 Transporter Protein

  2007cited by this paper
• Pharmacogenomics in colorectal cancer: the first step for individualized-therapy.

  2007cited by this paper
• Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies.

  2007cited by this paper
• DPYD*2A mutation: the most common mutation associated with DPD deficiency

  2007cited by this paper
• Pharmacogenetics of EGFR and VEGF inhibition.

  2007influential reference
• Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy

  2007cited by this paper
• Distribution of calcineurin activity in blood cell fractions and impact of tacrolimus inhibition

  2006cited by this paper
• Pharmacokinetics and pharmacodynamics of irinotecan and its metabolites from plasma and saliva data in patients with metastatic digestive cancer receiving Folfiri regimen

  2006cited by this paper
• Association of genetic polymorphisms in the base excision repair pathway with lung cancer risk: a meta-analysis.

  2006cited by this paper
• ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer.

  2006influential reference
• The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer.

  2006cited by this paper
• Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986.

  2005cited by this paper
• Molecular Alterations in Tumors and Response to Combination Chemotherapy with Gefitinib for Advanced Colorectal Cancer

  2005cited by this paper
• Risk of death in elderly users of conventional vs. atypical antipsychotic medications.

  2005cited by this paper
• Analysis of the DPYD Gene Implicated in 5-Fluorouracil Catabolism in a Cohort of Caucasian Individuals

  2005cited by this paper
• Interethnic variability of ERCC2 polymorphisms

  2005cited by this paper
• An accurate dihydrouracil/uracil determination using improved high performance liquid chromatography method for preventing fluoropyrimidines-related toxicity in clinical practice.

  2005cited by this paper
• Pharmacogenomic assessment of carboxylesterases 1 and 2.

  2004cited by this paper
• Rapid Identification of Dihydropyrimidine Dehydrogenase Deficiency by Using a Novel 2-13C-Uracil Breath Test

  2004cited by this paper
• A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer

  2004cited by this paper
• Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.

  2004cited by this paper
• Methylenetetrahydrofolate reductase gene polymorphisms and response to fluorouracil-based treatment in advanced colorectal cancer patients.

  2004cited by this paper
• Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.

  2004cited by this paper
• Dihydropyrimidine dehydrogenase deficiency: impact of pharmacogenetics on 5-fluorouracil therapy.

  2004cited by this paper
• Should Screening for DPD Deficiency Be Mandatory before 5-FU Exposure?

  2004cited by this paper
• Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes.

  2004cited by this paper
• Pharmacogenetics of human carboxylesterase 2, an enzyme involved in the activation of irinotecan into SN‐38

  2004influential reference
• Tumor dihydropyrimidine dehydrogenase expression is a useful marker in adjuvant therapy with oral fluoropyrimidines after curative resection of colorectal cancer

  2004cited by this paper
• Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis.

  2004cited by this paper
• Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic Pathways

  2004cited by this paper
• Phase II study of capecitabine, oxaliplatin, and erlotinib in previously treated patients with metastastic colorectal cancer.

  2004cited by this paper
• Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

  2004cited by this paper
• FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.

  2004cited by this paper
• Frequency of C3435T single nucleotide MDR1 genetic polymorphism in an Asian population: phenotypic-genotypic correlates.

  2003cited by this paper
• Sensitive HPLC-fluorescence method for irinotecan and four major metabolites in human plasma and saliva: application to pharmacokinetic studies.

  2003cited by this paper
• Irinotecan pathway genotype analysis to predict pharmacokinetics.

  2003cited by this paper
• Pharmacogenomics of ABC transporters and its role in cancer chemotherapy.

  2003cited by this paper
• Determination of serine/threonine protein phosphatase type 2B PP2B in lymphocytes by HPLC.

  2003cited by this paper
• Dihydropyrimidinase deficiency and severe 5-fluorouracil toxicity.

  2003cited by this paper
• Increased risk of grade IV neutropenia after administration of 5‐fluorouracil due to a dihydropyrimidine dehydrogenase deficiency: High prevalence of the IVS14+1g>a mutation

  2002cited by this paper
• Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer.

  2002cited by this paper
• Human colon cancer cells surviving high doses of cisplatin or oxaliplatin in vitro are not defective in DNA mismatch repair proteins

  2002cited by this paper
• Prognostic value of tumoral thymidylate synthase and p53 in metastatic colorectal cancer patients receiving fluorouracil-based chemotherapy: phenotypic and genotypic analyses.

  2002cited by this paper
• Implications of dihydropyrimidine dehydrogenase on 5-fluorouracil pharmacogenetics and pharmacogenomics.

  2002cited by this paper
• Irinotecan pharmacokinetics-pharmacodynamics: the clinical relevance of prolonged exposure to SN-38

  2002cited by this paper
• Thymidylate synthase gene polymorphism predicts response to capecitabine in advanced colorectal cancer

  2002cited by this paper
• Human carboxylesterase 2 is commonly expressed in tumor tissue and is correlated with activation of irinotecan.

  2002influential reference
• ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy.

  2001influential reference
• A polymorphism of the XRCC1 gene predicts for response to platinum based treatment in advanced colorectal cancer.

  2001cited by this paper
• A Xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer.

  2001cited by this paper
• Phase I trial of pegylated liposomal doxorubicin and docetaxel in advanced breast cancer.

  2001cited by this paper
• Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy

  2001cited by this paper
• Prevalence of a common point mutation in the Dihydropyrimidine dehydrogenase (DPD) gene within the 5 '-splice donor site of

  2001cited by this paper
• Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5'-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)- related toxicity compared with controls.

  2001cited by this paper
• Can dihydropyrimidine dehydrogenase impact 5-fluorouracil-based treatment?

  2000cited by this paper
• Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis.

  2000cited by this paper
• Characterization of CPT-11 converting carboxylesterase activity in colon tumor and normal tissues: comparison with p-nitro-phenylacetate converting carboxylesterase activity

  2000cited by this paper
• Correlation between uracil and dihydrouracil plasma ratio, fluorouracil (5-FU) pharmacokinetic parameters, and tolerance in patients with advanced colorectal cancer: A potential interest for predicting 5-FU toxicity and determining optimal 5-FU dosage.

  1999influential reference
• Glucuronidation of 7-ethyl-10-hydroxycamptothecin (SN-38) by the human UDP-glucuronosyltransferases encoded at the UGT1 locus.

  1999influential reference
• Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity

  1999cited by this paper
• Oxaliplatin: mechanism of action and antineoplastic activity.

  1998influential reference
• Human glutathione S-transferase P1 polymorphisms: relationship to lung tissue enzyme activity and population frequency distribution.

  1998cited by this paper
• ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy.

  1998influential reference
• A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity.

  1998cited by this paper
• Semi-automated radioassay for determination of dihydropyrimidine dehydrogenase (DPD) activity. Screening cancer patients for DPD deficiency, a condition associated with 5-fluorouracil toxicity.

  1997cited by this paper
• A comprehensive review of 5‐fluorouracil and leucovorin in patients with metastatic colorectal carcinoma

  1997cited by this paper
• Biochemical modulation of fluoropyrimidines: is there an optimal (6R,S) leucovorin dose and schedule?

  1996cited by this paper
• The DCC protein and prognosis in colorectal cancer.

  1996cited by this paper

• RU486 Metabolite Inhibits CCN1/Cyr61 Secretion by MDA-MB-231-Endothelial Adhesion

  2019cites this paper
• Germ line polymorphisms as predictive markers for pre-surgical radiochemotherapy in locally advanced rectal cancer: a 5-year literature update and critical review

  2015cites this paper